Intelligence Services
China biotech intelligence,
customized to your deal.
From free weekly briefings to custom deal evaluations — the same primary Chinese-language sources that $500/hr consultants use, delivered at a fraction of the cost.
Weekly Briefing
The intelligence briefing that BD teams, VCs, and compliance officers read to navigate China biotech.
- ✓Deal of the Week analysis with term benchmarks
- ✓BIOSECURE compliance tracking and BCC status updates
- ✓CDE filing translations with BD context
- ✓Corporate ownership highlights
- ✓5 actionable takeaways per issue
Custom Engagement
Targeted intelligence for specific deals, entities, or compliance questions. The same databases that $500/hr consultants use — at a fraction of the cost.
- ✓Full deal structure evaluation with comp analysis
- ✓Complete beneficial ownership mapping (Tianyancha/GSXT)
- ✓BIOSECURE exposure assessment for specific supply chains
- ✓CDE filing translation and regulatory pathway analysis
- ✓Entity relationship diagrams with ownership percentages
- ✓Delivered as PDF report with executive summary
What we deliver
Deal Evaluation
Evaluating a China-origin licensing opportunity? We benchmark upfronts, milestones, and royalties against comparable China-to-West transactions. You get the comp set and structural precedents your term sheet needs.
"We benchmarked a Phase II ADC upfront against 14 comparable China deals from 2024-2026 and identified a 2.3x premium in the proposed terms — which the BD team used to negotiate $40M lower."
Entity Ownership Mapping
Need to know who really owns the Chinese company you're evaluating? We trace beneficial ownership through Tianyancha and GSXT corporate registries — VIE structures, SOE connections, subsidiary chains, and BIOSECURE-relevant relationships.
"We mapped 4 intermediate holding companies between a WuXi subsidiary and its ultimate beneficial owners — a finding that directly informed the client's BIOSECURE risk assessment."
BIOSECURE Compliance
Assess your supply chain exposure to potential BCCs. We identify which contracts touch designated or at-risk entities, map alternative providers, and provide a transition planning framework.
"We identified 3 indirect BGI dependencies in a mid-cap biotech's sequencing supply chain that their internal compliance team had missed — all through Chinese corporate registry analysis."
How it works
Share your question
Email us with the company, deal, or compliance question you need answered.
We scope and quote
Within 48 hours, you receive a scope of work and fixed-price quote. No surprises.
Primary source research
We pull data from CDE filings, Tianyancha, GSXT, and Chinese-language sources your team can't access.
Delivered as intelligence
You receive a PDF report with executive summary, data tables, and actionable recommendations.
Premium Intelligence
Corporate Intelligence Graph
Interactive ownership mapping across 60+ Chinese biotech and pharma companies. Trace deal partnerships, subsidiary chains, executive networks, and BIOSECURE exposure in real time.
Explore the GraphStart with the free briefing.
Most clients start as subscribers. See the quality of our analysis, then reach out when you need something specific.